Becton Dickinson downgraded to Market Perform from Outperform at Leerink Leerink downgraded Becton Dickinson citing a lack of visibility into improved pricing and utilization trends following the company's Q3 results. The firm lowered its price target for shares to $80 from $85. Note Becton Dickinson was also downgraded this morning at CLSA.
News For BDX From The Last 14 Days
Check below for free stories on BDX the last two weeks.
JDRF extends collaboratoin with Becton Dickinson JDRF and Becton Dickinson are accelerating the development of new products that combine BD's proprietary insulin infusion and glucose sensing technologies through a new collaboration announced. This new, three-year commitment is an extension of existing JDRF-BD collaborations focused on type 1 diabetes.
Becton Dickinson price target raised to $115 from $95 at Argus Argus increased its price target on Becton Dickinson as the firm expects the company to benefit from its new generic drug manufacturing business. The firm notes that this new business has high margins, and it keeps a Buy rating on the shares.